PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Thursday, March 31, 2022: Biosergen AB ("Biosergen" or the "Company") thereby publishes the interim report for the fourth quarter 2021. The interim report is available as an attached document and on the company website (www.biosergen.net)
Biosergen AB was registered in February 2021. On April 16, 2021, the company acquired Biosergen AS with the subsidiary Select Pharma PTY LTD and formed the group with Biosergen AB as parent company. The rules of reverse acquisitions are applied why Biosergen AS is to be seen as the parent company in the group in 2020. Hence 2020 comparative figures relate to Biosergen AS with its subsidiary Select Pharma Pty Ltd.
Summary of the Interim Report for Q4 2021
Amounts in SEK '000 Q4 Jan.-Dec. 2021 Jan.-Dec. 2020
Consolidated group 8 861 11 570 4 432
revenue
Consolidated group -14 950 -34 077 -6 226
loss before
depreciation
Consolidated group - 14 950 -34 077 -6 226
loss before net
financials
Consolidated net -15 034 -34 318 -6 724
result
Consolidated earnings -1,42
per share (EPS)
- On November 30, 2021, Biosergen AB announced publication of the interim report for the third quarter 2021
Highlights after the period
There have been no highlights after the period.
The Financial report can be found on our website: https://biosergen.net/investors/filings
For further information about Biosergen, please contact:
Dr. Peder M. Andersen, CEO
Telephone: +45 2080 2470
E-mail: peder.andersen@biosergen.net
Certified Adviser
Erik Penser Bank
Telefon: +46 8 463 8000
E-mail: certifiedadvisor@penser.se
This information is such information that Biosergen AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on March 31, 2022.